Mavyret is an antiviral drug prescribed to treat hepatitis C (HCV). It comes as oral tablets and pellets. Mavyret works by stopping HCV from multiplying, which can cure this condition. Mavyret is ...

FDA approved a label expansion for Mavyret for the treatment of acute hepatitis C virus, according to a press release from the manufacturer, AbbVie.

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus ...

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus infections in adults and children aged three years and older, without cirrhosis or ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes those with acute HCV. This development is significant as it ...

Drug Pharmacologic Class Indication More Information Cardiovascular Disease Widaplik (telmisartan, amlodipine and indapamide) Angiotensin II receptor ...

Mavyret was initially approved in 2017 for newly diagnosed adult Hepatitis C patients. AbbVie Inc. (NYSE:ABBV) is an international biopharmaceutical firm dedicated to creating and providing advanced ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

AbbVie (NYSE:ABBV) recently secured FDA approval for the expanded use of MAVYRET, a treatment for hepatitis C, which now includes younger patients and those with acute HCV. This development is ...